The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Phase III CERVINO trial: etentamig efficacy and safety in relapsed/refractory multiple myeloma
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses findings from the Phase III CERVINO trial (NCT06158841) evaluating etentamig, a BCMA-targeted bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma. He highlights improved response rates and progression-free survival compared with standard-of-care therapies, alongside a manageable safety profile and the convenience of once-every-four-week dosing. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
